洛哌丁胺（易蒙停）治疗回结肠疾病或切除术后所致慢性腹泻的双盲安慰剂对照研究
Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection.
作者信息
Mainguet P, Fiasse R
出版信息
Gut. 1977 Jul;18(7):575-9. doi: 10.1136/gut.18.7.575.
Abstract
Loperamide (R 18 553) was compared with placebo in a double-blind crossover study of 21 patients with chronic diarrhoea caused by ileocolic disease or resection. Eighteen patients completed the trial. At a median daily dose of 6 mg the new antidiarrhoeal preparation was found to be superior to placebo in controlling chronic diarrhoea. The frequency and weight of stools significantly decreased, the stools became more solid, and carmine transit time was prolonged during loperamide therapy. Loperamide was consistently preferred to placebo by the patients. Gastrointestinal side-effects were few and comparable during both treatment periods.
摘要
在一项针对21例因回结肠疾病或切除术后导致慢性腹泻患者的双盲交叉研究中，将洛哌丁胺（R 18 553）与安慰剂进行了比较。18例患者完成了试验。发现在每日中位剂量为6毫克时，这种新型止泻制剂在控制慢性腹泻方面优于安慰剂。在洛哌丁胺治疗期间，大便的频率和重量显著降低，大便变得更成形，并且胭脂红转运时间延长。患者一直更喜欢洛哌丁胺而非安慰剂。两个治疗期间的胃肠道副作用均较少且相当。
相似文献
1
Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection.洛哌丁胺（易蒙停）治疗回结肠疾病或切除术后所致慢性腹泻的双盲安慰剂对照研究
Gut. 1977 Jul;18(7):575-9. doi: 10.1136/gut.18.7.575.
2
3
A double-blind trial of loperamide in the treatment of chronic diarrhoea.洛哌丁胺治疗慢性腹泻的双盲试验。
S Afr Med J. 1979 Mar 24;55(13):502-3.
4
Loperamide (imodium)--clinical trial.洛哌丁胺（易蒙停）——临床试验。
Ther Hung. 1990;38(2):60-3.
5
A double blind crossover comparison of loperamide with diphenoxylate in the symptomatic treatment of chronic diarrhea.洛哌丁胺与地芬诺酯对症治疗慢性腹泻的双盲交叉比较。
Gastroenterology. 1976 Jun;70(6):1030-4.
6
Symptomatic treatment of acute infectious diarrhoea: loperamide versus placebo in a double-blind trial.
J Infect. 1986 Jan;12(1):35-8. doi: 10.1016/s0163-4453(86)94833-4.
7
Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea.洛哌丁胺：其药理学特性及对腹泻治疗效果的综述
Drugs. 1978 Jan;15(1):33-52. doi: 10.2165/00003495-197815010-00003.
8
[Clinical evaluation of loperamide (Imodium)].洛哌丁胺（易蒙停）的临床评估
Wiad Lek. 1989;42(13-15):849-53.
9
Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo-controlled study.洛哌丁胺用于慢性腹泻的症状控制。双盲安慰剂对照研究。
Ann Clin Res. 1975 Oct;7(5):325-30.
10
Treatment of chronic diarrhoea: loperamide versus ispaghula husk and calcium.慢性腹泻的治疗：洛哌丁胺与车前草纤维及钙的对比
Scand J Gastroenterol. 1988 Dec;23(10):1237-40. doi: 10.3109/00365528809090197.
引用本文的文献
1
Opioids in the Treatment of Chronic Idiopathic Diarrhea in Humans-A Systematic Review and Treatment Guideline.阿片类药物治疗人类慢性特发性腹泻——一项系统评价与治疗指南
J Clin Med. 2023 Mar 24;12(7):2488. doi: 10.3390/jcm12072488.
2
Diagnosis and Management of Microscopic Colitis in Pediatric Patients.儿童显微镜结肠炎的诊断和治疗。
Paediatr Drugs. 2022 May;24(3):217-233. doi: 10.1007/s40272-022-00504-3. Epub 2022 May 2.
3
European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.欧洲显微镜下结肠炎指南：欧洲胃肠病学联合会和欧洲显微镜下结肠炎小组声明与建议
United European Gastroenterol J. 2021 Feb 22;9(1):13-37. doi: 10.1177/2050640620951905.
4
Systematic review: the effect of right hemicolectomy for cancer on postoperative bowel function.系统评价：右半结肠切除术治疗结肠癌对术后肠功能的影响。
Support Care Cancer. 2020 Oct;28(10):4549-4559. doi: 10.1007/s00520-020-05519-5. Epub 2020 May 20.
5
Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options.结肠癌手术后的慢性腹泻——发生率、病因及治疗选择
Int J Colorectal Dis. 2018 Jun;33(6):683-694. doi: 10.1007/s00384-018-2993-y. Epub 2018 Mar 27.
6
Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice.阿片类拮抗剂在孕鼠体内向胎儿脑的优先递送
J Pharmacol Exp Ther. 2016 Jul;358(1):22-30. doi: 10.1124/jpet.115.231902. Epub 2016 May 5.
7
Treatment of IBD: where we are and where we are going.炎症性肠病的治疗：现状与未来。
Am J Gastroenterol. 2015 Jan;110(1):114-26. doi: 10.1038/ajg.2014.357. Epub 2014 Dec 9.
8
Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases.调控核纤层蛋白病和与年龄相关疾病中缺陷型核纤层蛋白 A 表达和积累的潜在治疗方法。
J Mol Med (Berl). 2012 Dec;90(12):1361-89. doi: 10.1007/s00109-012-0962-4. Epub 2012 Oct 23.
9
Antidiarrhoeal activity of loperamide: studies of its influence on ion transport across rabbit ileal mucosa in vitro.洛哌丁胺的止泻活性：其对兔回肠黏膜离子转运体外影响的研究
Gut. 1982 Nov;23(11):974-9. doi: 10.1136/gut.23.11.974.
10
Local inhibition of myoelectrical activity of human colon by loperamide.洛哌丁胺对人结肠肌电活动的局部抑制作用。
Dig Dis Sci. 1984 Mar;29(3):232-8. doi: 10.1007/BF01296257.
本文引用的文献
1
Relation of small bowel resection to nutrition in man.人体小肠切除与营养的关系。
Gastroenterology. 1960 Apr;38:605-15.
2
Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea.局限性回肠炎、回肠切除及甘露醇诱发腹泻中的胆盐吸收不良
J Clin Invest. 1968 Feb;47(2):261-7. doi: 10.1172/JCI105722.
3
The short gut syndrome: pathophysiology and treatment.短肠综合征：病理生理学与治疗
Curr Probl Surg. 1971 Jun:3-51.
4
Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides.合成止泻剂。2,2-二苯基-4-(4'-芳基-4'-羟基哌啶基)丁酰胺。
J Med Chem. 1973 Jul;16(7):782-6. doi: 10.1021/jm00265a009.
5
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 8: Clinical investigation. Use of a flexible dosage schedule in a double-blind comparison of loperamide with diphenoxylate in 614 patients suffering from acute diarrhea.洛哌丁胺（R 18 553），一种新型止泻药。第八部分：临床研究。在614例急性腹泻患者中，采用灵活剂量方案对洛哌丁胺与地芬诺酯进行双盲比较。
Arzneimittelforschung. 1974 Oct;24(10):1660-5.
6
7
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers.洛哌丁胺（R 18 553），一种新型止泻药。第6部分：临床药理学。正常志愿者中洛哌丁胺、地芬诺酯和可待因致便秘活性及安全性的安慰剂对照比较。
Arzneimittelforschung. 1974 Oct;24(10):1653-7.
8
A comparative double-blind study of two antidiarrhoeals, difenoxine and loperamide.两种止泻药——地芬诺辛和洛哌丁胺的双盲对照研究。
Tijdschr Gastroenterol. 1972;15(5):337-42.
9
Zotero 插件